NCT07139509View on ClinicalTrials.gov

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 3, 2024

Primary Completion Date

July 30, 2028

Study Completion Date

December 30, 2028

Conditions
Relapsed/Refractory Multiple Myeloma(MM)
Interventions
DRUG

allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells

dosage form: UCAR-T cell injection Route of Administration: Single intravenous injection Participants will receive lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (500 mg/m²/day) from Day -5 to -3, prior to UCAR-T cell infusion on Day 0.

Trial Locations (1)

710016

RECRUITING

Xi'an No.3 Hospital, Xi’an

All Listed Sponsors
collaborator

Ucello Therapeutics Co., Limited

INDUSTRY

lead

Xi'an No.3 Hospital

OTHER_GOV